My top 3 ASX shares to consider buying before April

Here are three vastly different companies that each offer a tantalising opportunity right now.

| More on:
A young man wearing glasses writes down his stock picks in his living room.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P/ASX 200 Index (ASX: XJO) is up 11.6% over the past year. Yet, I still believe there are top deals among ASX shares in this market. Yes, there are opportunities to discover even when the Australian share market is around all-time highs.

As April draws near (that was quick!), it's as good of a time as any to trawl through what is on offer. Despite headlines of a 'per capita recession' and whispers of an 'official recession' on the horizon, I will continue putting my money to work in quality companies — letting long-term compounding outweigh any temporary instability.

Here are a few ASX shares that meet my criteria for buying ahead of April this year.

Wonderful company at a fair price

The top echelon of companies usually trade on lofty valuations — everyone already knows how great they are. It makes it incredibly challenging to scoop up shares in such companies at a price that provides a margin of safety.

Occasionally, something that shatters a company's once-pearly perception — a rumour, a scathing report, or an innocent misstep — can occur. The reaction can be magnitudes greater than the actual issue, partially because the business loses that 'golden 'golden child' sheen.

In my view, Resmed CDI (ASX: RMD) is one such company. At a price-to-earnings (P/E) ratio of 31, the medical device maker's asking price is no tall order relative to its former glory.

The popularity of weight loss medications, such as Ozempic, has induced a slimming down of the Resmed share price. However, the market for sleep apnea treatments remains vast. Given the company's track record for growth, I'd happily buy more of this ASX share before the month ends.

A top ASX share with pricing power

A sensational FY23 full-year result has put this growth share on my radar. In my opinion, the combination of rapid growth and pricing power makes Life360 Inc (ASX: 360) highly attractive.

Companies that aren't yet generating profits can be hard to value. Nonetheless, the United States software maker appears to be heading in the right direction as it raises prices across its subscriber base.

For example, average revenue per 'paying circle' (essentially a family) rose 25% year-on-year amid the price increases. Positively, global paying circles still grew by 21% despite asking customers to pay more for the offering — evidence that Life360 wields some strong pricing power.

Furthermore, with 61 million global monthly active users, the runway for growth still seems lengthy. This ASX share is currently valued at a market capitalisation of $2.58 billion.

A winner from rate cuts

The third and final investment I'm contemplating this month is a bonafide value-style buy.

Famed value investor Benjamin Graham was known for his tendency to buy companies trading below their book value. This means the company's market capitalisation is less than its net assets, and Rural Funds Group (ASX: RFF) is an ASX share meeting this criteria.

The real estate investment trust (REIT) holds $1.9 billion of farmland and other agricultural assets. To do so, Rural Funds has taken on $701 million worth of debt to fund the purchase and improvement of property.

Because of this, the company stands to benefit if interest rates begin to fall later this year. Approximately one-fifth of the REIT's revenue was consumed by finance costs in the first half. Any reduction in interest expense will flow down to the bottom line of this ASX share.

Motley Fool contributor Mitchell Lawler has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Life360 and ResMed. The Motley Fool Australia has positions in and has recommended ResMed and Rural Funds Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

Man sitting in a plane seat works on his laptop.
Opinions

Expert reveals 2 ASX stocks to sell — and 1 is a recent IPO

Toby Grimm from Baker Young shares his insights.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Opinions

Expert's verdict on 3 ASX 200 shares (2 have doubled in value and the other has lost 29%)

Two of these stocks were the best performers of their sectors in FY25. Should you buy, hold, or sell?

Read more »

A male investor sits at his desk pondering at his laptop screen with a piece of paper in his hand.
Opinions

Where I'd invest in ASX shares ahead of the likely RBA rate cut

These stocks look too good to miss.

Read more »

Person pretends to types on laptop drawn in sand.
Opinions

I sold one of my oldest ASX 200 shares last week. Here's why

Why would I sell one of my longest-held stocks?

Read more »

Broker analysing the share price.
Materials Shares

Buy, hold, or sell? Broker's verdict on 3 ASX 200 materials shares

Materials was one of four market sectors that weakened in overall value in FY25.

Read more »

A person sitting at a desk smiling and looking at a computer.
Technology Shares

3 ASX 200 tech shares to buy in July: Experts

The ASX tech sector delivered outstanding returns for investors in FY25.

Read more »

A group of executives sit in front of computer screens in a darkened room while a colleague stands giving a presentation with a share price graphic lit up on the wall
Opinions

2 ASX 200 large-cap shares that this fundie is cashing in after phenomenal growth

Shaw and Partners portfolio manager James Gerrish says he knows this will be an 'unpopular call'.

Read more »

Woman and man calculating a dividend yield.
Opinions

Buy or bail? Fundie's verdict on 2 ASX 300 shares

Stuart Bromley of Medallion Financial Group provides his insights.

Read more »